When was Nuvalent founded?

Nuvalent was founded in 2017 and raised its 1st funding round 4 years after it was founded.

Where is Nuvalent located?

Nuvalent is headquartered in Cambridge, United States. It is registered at One Broadway 14th Floor Cambridge, Massachusetts 02142.

How many employees does Nuvalent have?

As of Sep 30, 2026, the latest employee count at Nuvalent is 306.

Is Nuvalent a funded company?

Nuvalent is a funded company, having raised a total of $185M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jan 27, 2021.

How much is Nuvalent worth?

The last known valuation of Nuvalent was $***** as of Jul 26, 2021.

When was the latest funding round of Nuvalent?

Nuvalent's latest funding was a $***** Series B round on May 11, 2021, with participation from 12 investors.

Where does Nuvalent rank among its competitors?

Nuvalent ranks 141st amongst 3383 active competitors, of which 1134 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Nuvalent?

Nuvalent's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Nuvalent - 2026 Company Profile, Team, Funding, Competitors & Financials

Q: Is Nuvalent an acquired company?

Nuvalent got acquired by GSK on Jun 09, 2026.

Company Details

Developer of therapeutic solutions for the treatment of cancer. The company is involved in the development of a novel drug candidate NUV-520 that is a ROS1-selective inhibitor that provides solutions for patients with NSCLC tumors. It also provides treatment solutions for patients with CNS metastasis. The drug candidate NUV-655 provides solutions for the treatment of lung cancer, breast cancer, & others.

Website: nuvalent.com
Social
Registered Address: One Broadway 14th Floor Cambridge, Massachusetts 02142

Key Metrics

Founded Year

2017

Location

Cambridge, United States

Stage

Acquired

Total Funding

$185M in 2 rounds

Latest Funding Round

Series B, May 11, 2021, $*****

Last Known Valuation

$***** as on Jul 26, 2021

Investors

Deerfield & 11 more

Ranked

141^st among 3383 active competitors

Employee Count

306 as on Sep 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3052 more

Exit Details

Acquired by GSK (Jun 09, 2026)

View Nuvalent's full profile

Nuvalent is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Nuvalent, Inc. CIN: 6203574 , United States, Active	Jan 24, 2017	-	92 (As on Dec 31, 2023)	-

Nuvalent got acquired by GSK on Jun 09, 2026 at an acquisition amount of $*****.

Click here to take a look at Nuvalent's acquisition in detail

Nuvalent has raised a total funding of $185M over 2 rounds. Its first funding round was on Jan 27, 2021. Its latest funding round was a Series B round on May 11, 2021 for $*****. 12 investors participated in its latest round. Nuvalent has 12 institutional investors.

Here is the list of recent funding rounds of Nuvalent:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 11, 2021	2688243	Series B	2835795	4143323	9247647	1794323
Jan 27, 2021	5050119	Series A	9133535	9243389	Deerfield	9727465

Access funding benchmarks and valuations. Sign up today!

View details of Nuvalent's funding rounds and investors

Nuvalent's employee count trend

Nuvalent has 306 employees as of Sep 26. Here is Nuvalent's employee count trend over the years:

Uncover Nuvalent's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Nuvalent include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Nuvalent, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
141st	Nuvalent 2017, Cambridge (United States), Acquired	Developer of therapeutic solutions for the treatment of cancer	$185M	Bain Capital Life Sciences, Venrock & 10 others	63/100